IP Library Granted Patent US 7,803,178
Granted Patent B2
US 7,803,178 · App. 10/769,532 · Granted Sep 28, 2010

Inflatable porous implants and methods for drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,178
App. No.
10/769,532
Granted
Sep 28, 2010
Kind
B2
Abstract

The present invention provides inflatable porous implants, such as grafts, stent-grafts, and bladders, as well as methods and kits for drug delivery. In particular, the grafts and stent-grafts of the present invention provide for the delivery of a therapeutic agent into a flow conduit in the body. The inflatable porous implants provide for direct delivery of larger, more precise dosages of drugs over longer administration periods into the body. Moreover, these inflatable porous implants are often flexible when inserted and have a low profile delivery configuration for easy placement. The implants of the present invention further provide a mechanical or structural function in addition to drug delivery in a single integrated structure.

Claims (52)

1. A graft comprising:

a graft body section having a proximal end, a distal end, and defining at least one inflatable porous channel;

at least one inflatable porous cuff disposed at the proximal or distal end of the graft body section and in fluid communication with the at least one channel, wherein the at least one inflatable porous cuff is disposed in an axisymmetric cylindrical manner around the proximal or distal end of the graft body section; and

an inflation medium including at least one therapeutic agent configured to be introduced into the inflatable channel;

wherein the inflation medium comprises a curable liquid comprising a therapeutic agent-carrying host polymer.

2. The graft of claim 1 wherein the agent is capable of being transported from the inflation medium through a wall of the porous channel and released into a body lumen.

3. The graft of claim 2 wherein the agent is configured to be released into the body lumen from a luminal or abluminal surface of the graft body section.

4. The graft of claim 2 wherein the porous channel has varying levels of porosity.

5. The graft of claim 2 wherein the graft body section comprises one or more materials selected from the group consisting of a fluoropolymer, a polyethyleneterephthalate, a polyvinylchloride, a polyurethane, a polyolefin, and a polyamide.

6. The graft of claim 2 wherein the graft body section comprises expanded or perforated polytetrafluoroethylene.

7. The graft of claim 2 wherein a quantity of the agent releasable into the body lumen ranges from about 10 micrograms to about 100 milligrams.

8. The graft of claim 2 wherein the therapeutic agent is configured to be transported into the body lumen in a time period ranging from about seven days to about twelve months.

9. The graft of claim 2 wherein the at least one therapeutic agent comprises one or more agents selected from the group consisting of an endothelialization promoting agent, an angiogenesis promoting agent, an anti-thrombotic agent, an anti-aneurysmal agent, an anti-infection agent, an anti-inflammatory agent, an anti-restenosis agent, a chemotherapeutic agent, and an anti-cancer agent.

10. The graft of claim 1 wherein the therapeutic agent is capable of being released by diffusion through the host polymer.

11. The graft of claim 1 wherein the therapeutic agent is capable of being released by degradation of the host polymer.

12. The graft of claim 1 wherein the graft body section comprises biocompatible material capable of inhibiting transport of a bulk of the host polymer.

13. The graft of claim 1 wherein the host polymer is capable of being introduced into the inflatable channel before, during, or after graft deployment or implantation.

14. The graft of claim 1 wherein the inflation medium has a cure time ranging from about three minutes to about twenty minutes and a post-cure elastic modulus ranging from about 50 psi to about 400 psi.

15. The graft of claim 1 wherein the channel comprises one or more features selected from the group consisting of helical spirals, longitudinal channels, and circumferential rings.

16. The graft of claim 1 wherein the at least one inflatable porous cuff is disposed at the proximal end of the graft body section and further comprising at least one second inflatable porous cuff disposed at the distal end of the graft body section in fluid communication with the at least one channel, wherein the at least one second inflatable porous cuff is disposed in an axisymmetric cylindrical manner around the distal end of the graft body section.

17. A graft comprising:

a graft body section having a proximal end, a distal end, and defining at least one inflatable porous channel therebetween;

a connector member affixed to the proximal or distal end of the graft body section, the connector member comprising one or more connector elements;

a stent comprising one or more proximal stent connector elements coupled to the one or more connector member connector elements wherein the stent comprises a multi-crown configuration; and

a curable inflation medium including at least one therapeutic agent configured to be introduced into the inflatable channel.

18. The graft of claim 17 , wherein the curable inflation medium comprises a curable liquid.

19. The graft of claim 17 wherein the connector member comprises a multi-apex configuration.

20. The graft of claim 19 wherein the connector member comprises a twelve-apex configuration.

21. The graft of claim 17 wherein the stent comprises a three-crown portion.

22. The graft of claim 17 wherein the stent comprises a six-crown portion.

23. The graft of claim 17 wherein the stent comprises a three-crown portion and a six-crown portion.

24. The graft of claim 17 wherein the connector member affixed to the proximal end of the graft body section; and further comprising

a second connector member affixed to the distal end of the graft body section, the second connector member comprising one or more second connector elements; and

a second stent comprising one or more proximal second stent connector elements coupled to the one or more second connector member connector elements, wherein the second stent comprises a multi-crown configuration.

25. The graft of claim 17 wherein the at least one therapeutic agent comprises one or more agents selected from the group consisting of an endothelialization promoting agent, an angiogenesis promoting agent, an anti-thrombotic agent, an anti-aneurysmal agent, an anti-infection agent, an anti-inflammatory agent, an anti-restenosis agent, a chemotherapeutic agent, and an anti-cancer agent.

26. A graft comprising:

a graft body section having a proximal end, a distal end, and defining at least one inflatable porous channel;

at least one inflatable porous cuff disposed at the proximal or distal end of the graft body section and in fluid communication with the at least one channel, wherein the at least one inflatable porous cuff is disposed in an axisymmetric cylindrical manner around the proximal end of the graft body section;

a connector member affixed to the proximal or distal end of the graft body section, the connector member comprising one or more connector elements;

a stent comprising one or more proximal stent connector elements coupled to the one or more connector member connector elements wherein the stent comprises a multi-crown configuration; and

an inflation medium including at least one therapeutic agent configured to be introduced into the inflatable channel;

wherein the inflation medium comprises a curable liquid.

27. The graft of claim 26 wherein the at least one inflatable porous cuff is disposed at the proximal end of the graft body section and further comprising at least one second inflatable porous cuff disposed at the distal end of the graft body section in fluid communication with the at least one channel, wherein the at least one second inflatable porous cuff is disposed in an axisymmetric cylindrical manner around the distal end of the graft body section.

28. The graft of claim 26 wherein the connector member comprises a multi-apex configuration.

29. The graft of claim 28 wherein the connector member comprises a twelve-apex configuration.

30. The graft of claim 26 wherein the stent comprises a three-crown portion.

31. The graft of claim 26 wherein the stent comprises a six-crown portion.

32. The graft of claim 26 wherein the stent comprises a three-crown portion and a six-crown portion.

33. The graft of claim 26 wherein the connector member affixed to the proximal end of the graft body section; and further comprising

a second connector member affixed to the distal end of the graft body section, the second connector member comprising one or more second connector elements; and

a second stent comprising one or more proximal second stent connector elements coupled to the one or more second connector member connector elements, wherein the second stent comprises a multi-crown configuration.

34. The graft of claim 26 wherein the at least one therapeutic agent comprises one or more agents selected from the group consisting of an endothelialization promoting agent, an angiogenesis promoting agent, an anti-thrombotic agent, an anti-aneurysmal agent, an anti-infection agent, an anti-inflammatory agent, an anti-restenosis agent, a chemotherapeutic agent, and an anti-cancer agent.

Assignments (15)
SECURITY INTEREST Recorded Apr 1, 2021
From: TRIVASCULAR, INC.
To: SILICON VALLEY BANK
Reel/Frame 055794/0938 →
CHANGE OF NAME Recorded Oct 2, 2020
From: ENDOLOGIX, INC.
To: ENDOLOGIX LLC
Reel/Frame 053971/0135 →
SECURITY INTEREST Recorded Oct 2, 2020
From: ENDOLOGIX LLC (F/K/A ENDOLOGIX, INC.); NELLIX, INC.; TRIVASCULAR TECHNOLOGIES, INC.; TRIVASCULAR, INC.; TRIVASCULAR CANADA, LLC
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P.
Reel/Frame 053971/0052 →
SECURITY INTEREST Recorded Aug 10, 2018
From: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
To: DEERFIELD ELGX REVOLVER, LLC, AS AGENT
Reel/Frame 046762/0169 →
RELEASE OF SECURITY INTEREST Recorded Jan 12, 2018
From: DEERFIELD ELGX REVOLVER, LLC, AS AGENT
To: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
Reel/Frame 045059/0971 →
SECURITY INTEREST Recorded Apr 3, 2017
From: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P., AS AGENT
Reel/Frame 042141/0354 →
SECURITY INTEREST Recorded Apr 3, 2017
From: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
To: DEERFIELD ELGX REVOLVER, LLC, AS AGENT
Reel/Frame 042146/0454 →
RELEASE OF SECURITY INTEREST IN PATENT RIGHTS Recorded Feb 4, 2016
From: CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: TRIVASCULAR, INC.
Reel/Frame 037701/0097 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Oct 12, 2012
From: TRIVASCULAR, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 029117/0323 →
RELEASE OF SECURITY INTEREST Recorded Nov 16, 2010
From: BOSTON SCIENTIFIC CORPORATION
To: TRIVASCULAR, INC.
Reel/Frame 025365/0673 →
CHANGE OF NAME Recorded Jul 13, 2010
From: TRIVASCULAR2, INC.
To: TRIVASCULAR, INC.
Reel/Frame 024672/0321 →
CHANGE OF NAME Recorded Jun 2, 2008
From: BOSTON SCIENTIFIC SANTA ROSA CORP.
To: TRIVASCULAR2, INC.
Reel/Frame 021025/0102 →
CHANGE OF NAME Recorded Nov 15, 2005
From: TRIVASCULAR, INC.
To: BOSTON SCIENTIFIC SANTA ROSA CORP.
Reel/Frame 016782/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2004
From: TRIVASCULAR, INC.
To: BOSTON SCIENTIFIC CORPORATION
Reel/Frame 015409/0438 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2004
From: WHIRLEY, ROBERT G.; SHAPIRO, JAMES M.
To: TRIVASCULAR, INC.
Reel/Frame 014954/0023 →